Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2022-08-03 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FDA CLEARANCE OF ORAL RDRP INHIBITOR ASC10 TO CONDUCT A RANDOMIZED, PLACEBO CONTROLLED PHASE Ib STUDY IN MILD-TO-MODERATE COVID-19 PATIENTS
Capital/Financing Update Classification · 90% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding FDA clearance to conduct a Phase Ib clinical trial for a drug candidate ASC10. It contains no financial data, no detailed financial statements, and no regulatory filings or certifications. The content focuses on clinical trial initiation and drug development updates, which is typical for a Capital/Financing Update or a general corporate announcement. However, since it is about FDA clearance and clinical trial initiation, it aligns best with Capital/Financing Update (CAP) as it relates to the company's development activities and potential future capital implications. The document is short (4402 characters) and is an announcement, not a full report or transcript. Therefore, the most appropriate classification is CAP with high confidence.
2022-08-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 July 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on authorized and issued shares, share options, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. The content is regulatory in nature, providing updates on share capital and share movements rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a report or presentation. It is a regulatory submission related to share capital movements and confirmations, fitting best under Regulatory Filings (RNS).
2022-08-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued shares, share options, and related confirmations for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules. The content includes detailed tables on share capital, issued shares, share options, and confirmations, typical of regulatory compliance filings related to share capital changes. There is no indication that this is an annual or interim financial report, earnings release, or management discussion. The document is not a simple announcement but a structured regulatory filing about share capital and share movements. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes. The document length (5783 characters) and detailed content support this classification with high confidence.
2022-08-02 English
NOTICE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. regarding a scheduled board meeting to consider and approve the interim results for the six months ended June 30, 2022, and the potential recommendation of an interim dividend. It does not contain the actual interim financial report or detailed financial data but merely notifies the market of the upcoming board meeting and the agenda items. The document length is only 1326 characters, which is quite short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement about the timing and agenda of a report, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2022-07-27 English
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 100% confidence The document is titled 'Amended and Restated Memorandum and Articles of Association' of World Houseware (Holdings) Limited, adopted by special resolution on 14 June 2022. It contains detailed company constitutional documents including the memorandum of association and articles of association, which define the company's objects, powers, share capital, and internal governance rules. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is a governance-related document detailing the company's internal rules and structure. Therefore, the appropriate classification is Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the articles, not a brief announcement or summary.
2022-07-26 English
CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of World Houseware (Holdings) Limited regarding a change of address of the Hong Kong Branch Share Registrar and Transfer Office. It is a short announcement (1665 characters) and does not contain any financial data, report content, or detailed management discussion. It is not a report itself but an operational update related to company administration. This type of announcement does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not related to board changes, voting results, or capital changes. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-22 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.